ClinicalTrials.gg
RecruitingNCT04489992Updated May 26, 2023

Experiment on the Use of Innovative Computer Vision Technologies for Analysis of Medical Images in the Moscow Healthcare System

An observational study in AI (Artificial Intelligence), Mammary Cancer and Lung Cancer, sponsored by Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department. Recruiting at 1 site in Russian Federation. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-26.

Sponsored by Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2024, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started Feb 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
133,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 180 studies in Breast Neoplasms with a site in Russian Federation — 9 open to participants now, 10 under way, 1 of them phase 3. Breast Neoplasms · Russian Federation.

Planned enrollment
Largest of 13
133,000 · median 300
Started
2020
with 3 others
Observational
13 of 180
2 open now
Registered
161st of 180
by date

Among the 180 studies in Breast Neoplasms with a site in Russian Federation, this one has the largest planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2020, is one of 13 observational ones, and was the 161st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 180 studies in Breast Neoplasms with a site in Russian Federation are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies in Breast Neoplasms with a site in Russian Federation, or all of them as a file.
02

Study summary

It is planned to integrate various services based on computer vision technologies for analysis of the certain type of x-ray study into Moscow Unified Radiological Information Service (hereinafter referred to as URIS).

As a result of using computer vision-based services, it is expected:

  1. Reducing the number of false negative and false positive diagnoses;
  2. Reducing the time between conducting a study and obtaining a report by the referring physician;
  3. Increasing the average number of radiology reports provided by a radiologist per shift.
Read the detailed description

Recently a growth in the number of radiology studies across multiple modalities has been observed alongside the modest increase in staffing levels. This carries higher risks of increased workload and efficiency losses. The integration of computer vision-based services into URIS will improve the radiologists' productivity and job performance.

Existing prerequisites for conducting the study:

  1. Increasing the number of preventive and diagnostic radiological studies entails the growing workload for radiologists and increased risk of interpretation errors, which in turn leads to the decrease in quality of medical care.
  2. When a radiologist opens a worklist of studies, in the absence of special notes, he/she writes a report in the random order, not being able to select from the list the studies that require the most attention and prompt response (studies with pathological findings), which increases the time of diagnosis.
  3. The absence of the structured pre-filled template of report leads to the increase in time for preparing reports.
  4. A radiologist has to spend considerable time evaluating the dynamics of pathological changes, which also increases the time to prepare a report as well as the risk of error.
  5. Interpretation of preventive studies requires double reading, which is implemented inefficiently due to the staff shortage.

Study objectives:

  1. Study the diagnostic accuracy of the Services in accordance with the methodological guidelines No. 43 "Clinical trials of software based on intelligent technologies (diagnostic radiology)" (recommended by the Expert Council on Science of the Moscow Healthcare Department, Protocol No. 8 of June 25, 2019).
  2. Audit the studies conducted with Services application in order to determine the number of interpretation errors, and compare it with the audit result without their application (hypothesis 1).
  3. Conduct timekeeping to estimate time for preparing a report and the total number of evaluated studies with and without using the Services (hypothesis 2,3).
  4. Conduct a survey of radiologists who use the Services in their work, in order to determine their opinion about the implementation of innovative technologies in the diagnostic process.

METHODOLOGY

  1. The Experiment is carried out by the Moscow Healthcare Department in accordance with Regulation No. 43 of January 24, 2020 "On approval of the procedure and conditions for conducting the Experiment on the use of innovative computer vision technologies for analysis of medical images and further application in Moscow healthcare system".
  2. The experiment is conducted on the next types of studies:

1)Detection of CT signs consistent with COVID-19 (coronavirus) lung involvement (Chest CT); 2) Emphysema extent (Chest CT); 3) Detection of CT signs consistent with malignant neoplasm in the lungs (Chest CT); 4) Detection of LDCT signs consistent with malignant neoplasm in the lungs (Chest LDCT); 5) Detection and localization of compression vertebral fractures with a degree of vertebral body deformity of over 25% according to the Genant semi-quantitative scale, grades 2-3 (Chest CT); 6) Detection of free pleural fluid (effusion) (Chest CT); 7) Detection of enlarged intrathoracic lymph nodes (lymphadenopathy) (Chest CT); 8) Detection of bronchiectasis (Chest CT); 9) Detection of CT signs consistent with pulmonary tuberculosis (Chest CT); 10) Coronary calcium score (Chest CT/ LDCT); 11) Paricardial fat volume (Chest CT); 12) Dilation of ascending and descending thoracic aortas (Chest CT/ LDCT); 13) Dilation of the pulmonary trunk (Chest CT/ LDCT); 14) Detection of sarcoidosis (Chest CT); 15) Detection of signs consistent with the impairment of lung airness (Chest CT); 16) Detection of signs consistent with the focal lesions in the chest bones (Chest CT); 17) Detection of CT signs consistent with rib fracture (Chest CT); 18) Detection of signs of urolithiasis (Abdominal CT); 19) Detection of signs consistent with the focal lesions in the skeleton bones (Abdominal CT); 20) Detection of liver lesions (Abdominal CT); 21) Detection of CT signs consistent with gallbladder stones (Abdominal CT); 22) Detection of CT signs consistent with renal lesions (Abdominal CT); 23) Measuring the abdominal aorta dilation (Abdominal CT); 24) Detection of adrenal lesions (Abdominal/Chest CT); 25) Detection and localization of compression vertebral fractures with a degree of vertebral body deformity of over 25% according to the Genant semi-quantitative scale, grades 2-3 (Abdominal CT); 26) Automation of routine liver measurements (dimensions, liver density, choledochus diameter, portal vein diameter) (Abdominal CT); 27) Automation of routine kidney measurements (kidney size, pelvicalyceal system size) (Abdominal CT); 28) Automation of routine measurements of spleen and pancreas (size, density of the spleen and pancreas) (Abdominal CT); 29) Detection of acute ischemic stroke and its ASPECTS score (Head CT); 30) Detection of hemorrhage and its automatic volume calculation in ml or cm³ (Head CT); 31) Automation of routine measurements (ventriculometry, displacement of median structures, measurement of the craniovertebral junction) (Head CT); 32) Detection and localization of (at least 7) signs consistent with the priority disease (Chest XR); 33) Detection of signs (at least one) consistent with bone fracture (MSS XR); 34) Detection of radiologic signs (at least one) consistent with arthrosis of the joints (MSS XR); 35) Detection of radiological signs (at least one) consistent with deforming arthrosis of the hip (MSS XR); 36) Detection of radiological signs (at least one) consistent with the fracture of the shoulder joint bones (MSS XR); 37) Detection of radiological signs (at least one) consistent with the fracture of the hip joint bones (MSS XR) 38) Detection of radiological signs (at least one) consistent with the fracture of the ankle joint bones (MSS XR).

  1. Detection of reduced pneumatization / opacity of the paranasal sinuses (Head XR) 40) Detection of signs (at least one) consistent with transverse flat foot (MSS XR) 41) Detection of signs (at least one) consistent with the longitudinal flat foot in the lateral plane (MSS XR); 42) Detection of the signs of osteoporosis: detection and localization of compression vertebral fractures with a degree of height loss of over 25% as well as the radio density measurements of vertebral bodies (Spine XR); 43) Detection of signs consistent with osteochondrosis in the frontal and/or sagittal plane (Spine XR); 44) Detection of signs consistent with scoliosis in the frontal plane (Spine XR); 45) Detection of signs consistent with spondylolisthesis in the sagittal plane (Spine XR); 46) Detection and localization of findings consistent with breast cancer (MMG); 47) Detection of multiple sclerosis (Brain MRI); 48) Detection and localization of intracranial neoplasms (extracerebral, intracerebral) (Brain MRI); 49) Automation of routine measurements (ventriculometry, displacement of median structures, measurement of the craniovertebral junction, changes in white matter, intracranial measurements) (Brain MRI); 50) Detection of signs consistent with the focal lesions in the cervical spinal cord (Cervical spine MRI); 51) Detection and localization of MRI signs (at least one) consistent with degenerative changes in the cervical discs on sagittal and axial T2-WI (Cervical spine MRI); 52) Detection and localization of MRI signs (at least one) consistent with degenerative changes in the thoracic discs on sagittal and axial T2-WI (Thoracic spine MRI); 53) Detection of signs consistent with the focal lesions in the thoracic spinal cord (Thoracic spine MRI); 54) Detection and localization of MRI signs (at least one) consistent with degenerative changes in the lumbosacral discs on sagittal and axial T2-WI (Lumbosacral spine MRI); 55) Detection of signs consistent with the focal lesions in the lumbosacral spinal cord (Lumbosacral spine MRI); 56) Detecting signs consistent with the areas of cartilage breakdown (chondromalacia) along the articular surfaces of the knee and the patellofemoral joint (Knee joint MRI); 57) Automated routine measurements of the prostate gland (dimensions) (Lesser pelvis MRI); 58) Automated routine measurements of the uterus (corpus and cervix: position, dimensions, displacements) (Lesser pelvis MRI).
  1. For each Service during the Experiment, a certain number of studies is provided for processing based on their type:
  1. CT/LDCT - 30 250 studies;
  2. XR - 55 000 studies;
  3. MMG - 48 500 studies;
  4. MRI - 22 500 studies.
  1. A methodology for including services in the Experiment has been developed. For each Service, the participation process in the Experiment consists of the following stages:
  1. selection;
  2. the preparatory stage;
  3. the main stage;
  4. the final stage.

During the Experiment, a radiologist will routinely be able to:

  • work on a sorted list of patients (triage);
  • work with images processed by the Service;
  • work with a pre-filled template of the radiological report on each study;
  • evaluate the work of the Service according to the developed questionnaire. During the Experiment, a patient will receive the individual plan of the follow-up support. It includes preventive examinations or observation as well as treatment by a specialist.

Systematization and final analysis of the Experiment results is carried out within three months from the completion date of the last Service participation in the Experiment.

Based on the results of the Experiment, recommendations can be prepared on the possibility to register certain services as a medical device (software).

03

Conditions studied

  • AI (Artificial Intelligence)
  • Mammary Cancer
  • Lung Cancer
  • X-Rays; Lesion
  • COVID-19
  • Chest--Diseases
  • Abdomen Disease
  • Brain Disease
  • Fractures, Bone

Keywords

  • AI (Artificial Intelligence)
  • Computed tomography
  • Low-dose CT
  • X-ray chest
  • mammography
  • COVID-19
  • Chest--Diseases
  • Abdomen Disease
  • Brain Disease
  • Fractures, Bone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

patients over the age of 18 attending outpatient clinics

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age (over 18 years)
  • Gender (male and female)
  • Referral for the study
  • Signed to participate in the Experiment
  • Chest computed tomography and Low-dose computed tomography for lung cancer detection or mammography for breast cancer detection or chest X-ray for lung pathology detection

Exclusion criteria

Exclusion Criteria:

  • Another type of study (including a different modality and anatomical area)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
133,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Standard radiology studies with AI

    The experiment is conducted on 10 types of studies with AI: 1. Chest CT/ LDCT with different pathologies; 2. Abdominal CT with different pathologies; 3. Head CT with different pathologies; 4. MSS XR with different fractures 5. Spine XR with different pathologies; 6. MMG; 7. Brain MRI with different pathologies; 8. Cervical spine MRI, Lumbosacral spine MR and Thoracic spine MRI with spine pathologies 9. Knee joint MRI 10. Lesser pelvis MRI.

  • Standard radiology studies without AI

    The experiment is conducted on 10 types of studies without AI: 1. Chest CT/ LDCT with different pathologies; 2. Abdominal CT with different pathologies; 3. Head CT with different pathologies; 4. MSS XR with different fractures 5. Spine XR with different pathologies; 6. MMG; 7. Brain MRI with different pathologies; 8. Cervical spine MRI, Lumbosacral spine MR and Thoracic spine MRI with spine pathologies 9. Knee joint MRI 10. Lesser pelvis MRI.

06

What researchers measure

Primary outcomes

  1. Number of errors

    Change of at least 30% in the number of errors in interpretation of the studies with using computer vision-based services compared to the number of errors in interpretation without their application.

    Time frame: Upon completion, up to 4 years

Secondary outcomes

  1. Report turnaround time

    Change of at least 30% of the time from the study completion to report finalization by a radiologist.

    Time frame: Upon completion, up to 3 year

  2. Number of reports

    Change of at least 30% in the number of radiology reports provided by a radiologist per shift.

    Time frame: Upon completion, up to 4 years

  3. Change in the errors of services per the feedback form

    Change of at least 30% in computer vision-based services errors as per integrated feedback form for radiologists in the PACS. Types of errors: 1. Technological defect (absent AI-generated series, partially generated AI series, DICOM SR and images mismatch, multiple conflicting results) 2. Major discrepancy (findings outside the region of interest, irrelevant findings) 3. Inaccurate diagnosis 4. Inaccurate lesion localisation 5. Inaccurate lesion classification 6. Other (free-text field)

    Time frame: Upon completion, up to 4 years

07

Study locations

1 of 1 sites recruiting
  • Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
    Moscow, Russian Federation
    Recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Jan 2024, 46 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 46 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2020
First posted
Jul 28, 2020
StartActual
Feb 21, 2020
Primary completionEst.
Jan 1, 2024
CompletionEst.
Jan 1, 2024
Last update
May 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04489992
Lead sponsor
Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
Responsible party
Sponsor
First posted
Jul 28, 2020
Start date
Feb 21, 2020
Primary completion
Jan 1, 2024 (estimated)
Completion
Jan 1, 2024 (estimated)
Last update
May 26, 2023

Study contacts

Kirill Arzamasov, PhD
Contact
ArzamasovKM@zdrav.mos.ru
+79152514838
Olga Omelyanskaya
Contact
OmelyanskayaOV@zdrav.mos.ru
+79263948149
Anton Vladzymyrskyy
study director · Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion